News Sentiment

CGEN sentiment intelligence

Compugen news scored across direct company coverage, industry context, sector read-through, source quality, and freshness.

Chart Weekly report Factors RSS feed
Weighted score 54 Balanced news tone 61 relevant articles
Exchange NASDAQ United States
Sector Healthcare Market context
Industry Biotechnology Read-through group
Latest close 2.01 Week of 19 Jun 2026
Weighted tone 54/100

Balanced news tone

Market reaction Balanced read

News tone and price action are not far from neutral.

Primary event Earnings

75/100 classification confidence.

Company focus 54

directly relevant articles

Source quality 3

high-authority source matches

Trend context Trend active

-1.5% over one week, -28.2% over four weeks, trend active, and near fair-value range.

Latest direct headline Neutral

Compugen Ltd (CGEN) Valuation: PE, PB & Fair Value Analysis

Market Reaction

Balanced read

61/100 confidence

News tone and price action are not far from neutral.

Primary event Earnings 75/100 classification
One-week reaction -1.5% Price digesting
Trend fit Trend active -28.2% over four weeks
Fair value 15.9% Near fair-value range

Sentiment Mix

Positive, neutral, negative

Weighted by relevance
Positive 19
Neutral 33
Negative 9

Relevance

Why the article matched

Direct first
Direct company coverage 54
Industry context 7
Sector context 0

Sources

Coverage mix

Publishers
Market source 12
Stock Titan 10
TradingKey 8
GuruFocus 4
Moomoo 4
simplywall.st 4
Investing.com 3
TradingView 2

Event Lens

What the news is about

Classified themes
Earnings 27
Market update 18
Analyst action 9
Balance sheet 3
Capital return 1
Macro sensitivity 1
Guidance 1
Deals and strategy 1

Sentiment Trail

Score over time

50 baseline
Above 50 Neutral zone Below 50

News Tape

Relevant headlines

Showing 31-60 of 61
Seeking Alpha Direct company coverage

Compugen: 'Buy' As Early Gastric Cancer Data Reinforces Rilvegostomig Program (NASDAQ:CGEN)

Compugen (CGEN) maintains a "Buy" rating due to advancing clinical programs and upcoming oncology catalysts. Its drug Rilvegostomig, partnered with AstraZeneca, shows promising phase 1b/2 data with a 70% cORR in HER2+ gastric cancer and will have new data presented at ASCO 2026.

Tone
Positive 70/100
Event
Analyst action
Published
19 May 2026 12:39
Source
Seeking Alpha
GuruFocus Direct company coverage

Compugen (CGEN) Reports Q1 Revenue and Long-Term Financial Stabi

Compugen Ltd (CGEN) reported Q1 revenue of $2.2 million and projected its cash reserves to support operations through 2029, maintaining a debt-free status. Despite a low P/E ratio of 7.47x suggesting it might be undervalued, its GF Score™ of 60 reflects moderate investment qualit

Tone
Neutral 50/100
Event
Earnings
Published
18 May 2026 22:10
Source
GuruFocus
Stock Titan Direct company coverage

Compugen Ltd. (NASDAQ: CGEN) files $400M shelf; $100M ATM with Leerink

Compugen Ltd. (NASDAQ: CGEN) has filed a shelf registration statement (Form F-3) to offer up to $400 million in various securities, including ordinary shares, debt securities, rights, warrants, and units. This includes a $100 million "at-the-market" (ATM) sales agreement with Lee

Tone
Neutral 50/100
Event
Balance sheet
Published
18 May 2026 21:10
Source
Stock Titan
Associated Press Direct company coverage

Compugen: Q1 Earnings Snapshot

Tone
Neutral 50/100
Event
Earnings
Published
18 May 2026 11:58
Source
Associated Press